Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has issued duplicate share certificates in lieu of the original share certificates reported lost/misplaced, details of which are enclosed. Sanofi to sell oldest India plant to Zentiva for 261 crore
Multinational drugmaker Sanofi has received approval from its board of directors to sell its oldest manufacturing facility in India at Ankleshwar (Gu Sanofi to sell oldest India plant to Zentiva for 261 crore
Multinational drugmaker Sanofi has received approval from its board of directors to sell its oldest manufacturing facility in India at Ankleshwar (Gu Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release - Sanofi India Limited to sell Ankleshwar site to Zentiva We enclose herewith a copy of press release on the above subject, contents of which are self-explanatory for your information and records. Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Meeting Updates
Slump Sale and transfer of the manufacturing facility of the Company at Ankleshwar, Gujarat. The Board of Directors of Sanofi India Limited (the Company) at its meeting held on 10th September 2019 approved a transaction for the slump sale and transfer of the manufacturing facility of the Company at Ankleshwar, Gujarat to Zentiva Private Limited for a consideration of Rs. 2,617 million, subject to customary working capital adjustments. This transaction is subject to approval of the members, which will be initiated by the Company through a postal ballot process and few other conditions as defined under the Business Transfer Agreement. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has issued duplicate share certificates in lieu of the original share certificates reported lost/misplaced, details of which are enclosed. Sanofi India Ltd - 500674 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (Listing Regulations)
The unaudited financial results of the Company for the quarter and half year ended 30th June 2019 were approved by the Board of Directors of the Company at its meeting held on 29th July 2019 and published on 31st July 2019. Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed the disclosures of related party transactions for the half year ended 30th June 2019 in the format specified in the applicable accounting standards. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has issued duplicate share certificates in lieu of the original share certificates reported lost/misplaced, details of which are enclosed. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed. Sanofi: Strong domestic portfolio keeps Street positive amid pricing pain
Analysts at Elara Capital say the company's portfolio being skewed toward the high-growing chronic products, coupled with its leadership position in basal insulin, gives it an edge over its peers